share_log

Oppenheimer Maintains Perform on Nektar Therapeutics, Lowers Price Target to $3

Benzinga ·  Mar 6, 2023 07:17

Oppenheimer analyst Jay Olson maintains Nektar Therapeutics (NASDAQ:NKTR) with a Perform and lowers the price target from $5 to $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment